The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…
Search results for: lymphoma
When Immunodeficiency & Autoimmunity Coexist
When a patient has both primary immune deficiency and autoimmune disease, the combination can lead to life-threatening complications. Here are some insights into the challenges of diagnosing and treating this rare subset of patients…
2 Markers May Help Predict Who will Progress to Sjögren’s
Physicians already know a great deal about Sjögren’s syndrome’s symptoms and potential complications, and a new study confirms data on two long-suspected predictors of progression (i.e., measurable phenotypic findings) that could show which patients are likely to progress to active disease: hypergammaglobulinemia and hypocomplementemia. Published in the February issue of Arthritis Care & Research, “Natural…
Nivolumab-Induced Arthritis
Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…
Immune Checkpoint Inhibitors & Immune-Related Adverse Events
Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…
The Promise of Molecular Medicine
Honestly, I’m not sure why I bothered to listen. I was in my kitchen, early on a Saturday morning, with the radio keeping me company. It started with the news and the usual litany of tragedies, both major and minor, that comprise such programs. The news gradually faded into other programming, which I can no…
Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
Since they were first introduced in 2011, immune checkpoint inhibitors (ICIs) have become an important treatment for an expanding list of advanced cancers. Some concerns have been raised around the mechanism of action of these immunotherapy agents, making their use in rheumatic diseases (RD) problematical. An article in the March 2018 issue of Arthritis &…
IgG4-Related Kidney Disease: Diagnostics, Manifestations & More
Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…
Transcriptional Programming Research, & a Twist on CAR-T Cell Therapy
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting this past November, an expert said researchers are making progress in identifying drugs that can correct problems with transcriptional programming, which, if perfected, could go a long way toward harnessing more fully the power of genetics knowledge and directing it toward patient care. The session also delved into…
Turbocharge Your Cell Analysis with Mass Cytometry
SAN DIEGO—In his doctoral work, Sean Bendall, PhD, assistant professor of pathology and a researcher at Stanford University in Palo Alto, Calif., worked on protein identification and embryonic stem cell biology. That required examining the characteristics of cells—lots of cells. He was struck by how inefficient the process was. “The issue was, every experiment I…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 15
- Next Page »